About Us
About
J-Bio is a Tokyo-based venture that enables global Pharma and Biotech firms to identify and acquire or license in pre-clinical through clinical assets from Japanese pharmaceutical companies, bio ventures and academia.
J-Bio’s four founding partners have extensive combined experience in business development, private equity, M&A, venture capital, drug discovery and clinical development in Japan and the US. We are a veteran, multi-cultural team.
The Issue
-
US companies want better access to the gems of Japanese drug discovery, but few companies have been able to develop their desired level of access.
-
Japanese Pharma, Biotech firms and academia have a history of strong innovation in the development of pharmaceutical assets, yet Japan has been less successful in the commercialization of its research.
-
Additionally, some Japanese marketed drugs have not been partnered and launched in relevant worldwide markets.
-
Japanese bio ventures struggle to form collaborations with global firms due to challenges with communication, resources and network.
-
Identifying target assets and subsequently negotiating mutually-beneficial partnerships is extremely challenging to achieve from afar.
Our Goal
Our veteran team came together to solve these exact needs for Japanese and global partners.
We have the experience and access to succeed.
Our Access
-
We have relationships with all pharmaceutical companies in Japan conducting new drug development.
-
We know responsible people at more than half of the government-authorized technology licensing offices (TLOs) nationwide.
-
We have direct connections at 80% of the active bio ventures conducting drug R&D in Japan, and can access the remainder through our network.
Our Access
-
We have relationships with all pharmaceutical companies in Japan conducting new drug development.
-
We have direct connections at 80% of the active bio ventures conducting drug R&D in Japan, and can access the remainder through our network.
-
We know responsible people at more than half of the academic technology licensing offices (TLOs) nationwide.
Our Approach
J-Bio focuses on a small number of non-competing engagements. Through our structured and disciplined process of identifying, assessing suitability and negotiating the acquisition or licensing of assets, we create beneficial outcomes for our global clients.
Our close relationship with the Japanese biopharma ecosystem, academia and the government enables J-Bio to effectuate additional positive outcomes for global biopharmas including joint ventures and collaborative endeavors in Japan.
